NCT00044668 - Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

AC2993

Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.

Trial Locations (3)

H 1036

Diagnostic Units Hungary Kft., Budapest

H 1076

Peterfy Teaching Hospital, Budapest

H 1145

Uzsoki Street Municipal Hospital, Budapest